Philip W. Kantoff, M.D.
Professor, Department of Medicine, Harvard Medical School
Associate Physician, Medicine, Brigham And Women's Hospital
Director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
DF/HCC Program Affiliation
Prostate Cancer, Leader
Translational Pharmacology and Early Therapeutic TrialsCancer Genetics
DF/HCC Associations
Principal Investigator, Prostate Cancer SPORE
Member, Clinical Science Coordinating Committee
Member, Center Scientific Council
Research Abstract
Our research team focuses on the molecular basis of genitourinary cancers and improved treatments for patients with prostate cancer, kidney cancer, bladder cancer, and testicular cancer. Laboratory research involves understanding the genetics of prostate cancer, while clinical research focuses on trials of novel therapeutics for genitourinary cancers.
In our laboratory, we have investigated germline and somatic genetic markers of prostate cancer phenotype.
Our clinical trials have focused on:
- introducing chemotherapy or novel therapeutics to patients with high-risk localized prostate cancer
- testing novel therapeutics in men with rising levels of prostate-specific antigen (PSA) following local therapy with agents such as rosiglitazone and celecoxib
- testing novel theraputics in men with advanced prostate disease
- treating renal cell carcinoma with antiVEGF-based therapies.
Publications
No representative citations available.
